###### Strengths and limitations of this study

-   The Drug-induced Arrhythmia Risk Evaluation study has allowed the development of a cohort of cases of proarrhythmia.

-   These cases have provided crucial safety information, as well as underlying clinical and genetic data.
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-   Only patients who did not die as a result of the proarrhythmia could be included.

-   Referral of cases by cardiologists alone may have led to the underestimation of the prevalence of drug-induced arrhythmia from non-cardiac drugs.

-   The analysis of ethnicity and differences in risk of QT prolongation could not be investigated.

Introduction {#s1}
============

Drug-induced arrhythmia, or proarrhythmia, is the induction or exacerbation of cardiac arrhythmia associated with administration of a drug. The majority of drug-induced arrhythmic events relate to marked prolongation of the QT interval of the ECG, which can lead to the distinctive polymorphic ventricular tachycardia (VT) and 'Torsades de Pointes' (TdP), which in turn may lead to ventricular fibrillation (VF) and sudden death.[@R1] This is also known as the acquired long QT syndrome (aLQTS). Occasionally polymorphic and monomorphic VT without QT prolongation can occur.[@R2] In addition to drugs, other causes of aLQTS include endocrine disorders,[@R4] cirrhosis,[@R5] HIV and AIDS,[@R6] inflammation and immunity,[@R7] autoimmune disease,[@R8] structural heart disease,[@R9] electrolyte imbalances[@R10] and eating disorders.[@R11]

Drug-induced arrhythmia is associated with the use of cardiovascular agents (particularly class III antiarrhythmic drugs) and also with many non-cardiovascular indicated drugs within different therapeutic categories, including antihistamines, antipsychotics and antimicrobials; an up-to-date list is maintained on the CredibleMeds register (Azcert, <https://crediblemeds.org/>). Currently, there is substantial evidence to support a clear association between over 50 different drugs and risk of TdP, even when taken according to the terms of the marketing authorisation, with a number of these being withdrawn from the market.[@R12] Mechanistic proposals for clinical features such as electrolyte imbalance include block of the rapid form of the delayed rectifier potassium current (I~Kr~) in cardiomyocytes.[@R15] Genetic factors have also been identified. These include single nucleotide polymorphisms in the *NOS1AP* gene encoding the nitric oxide synthase 1 adaptor protein[@R18]; and mutations in potassium channel genes *KCNH2, KCNQ1, KCNE1* and *KCNE2* and/or the sodium channel gene *SCN5A*.[@R19] Such mutations are also recognised to cause congenital long QT syndrome (cLQTS).[@R21] Other notable risk factors include female sex, bradycardia, recent cardioversion, pre-existing electrolyte disturbance, elevated plasma concentrations and/or rapid infusion of QT-prolonging drugs and digitalis toxicity.[@R22]

Following the removal of several QT-prolonging drugs because of associated sudden deaths,[@R25] risk minimisation strategies were introduced to mitigate the arrhythmic risk posed by drugs, including clinical studies to assess the proarrhythmic potential for a new drug within the premarketing development programme.[@R29] However it has been recognised that there remain limitations in the conduct of clinical studies designed to evaluate a drug's potential for QT prolongation and applicability of results to vulnerable patients.[@R30] Because of the unpredictable nature of the condition, the Drug-induced Arrhythmia Risk Evaluation (DARE) study aimed to improve the understanding of the epidemiology of proarrhythmia by establishing a cohort of cases of drug-induced arrhythmia reported throughout England, to characterise typical patients with proarrhythmia and to describe the drugs found to be culpable in these cases of proarrhythmia. This manuscript is a per-protocol descriptive analysis of risk factors for the condition and the contribution of individual drugs to the risk of drug-induced arrhythmic events.

Methods {#s2}
=======

Study design and setting {#s2a}
------------------------

Cardiologists across England were notified of the study by the British Pacing and Electrophysiology Group and the British Cardiac Society and asked to recruit patients. Study awareness and participation was further promoted by project presentation and local interaction across the country. Cases of suspected proarrhythmia were referred by cardiologists in England between March 2003 and July 2011. All consenting cases attended a face-to-face interview with a regional study nurse (North, South or Midlands regions) between May 2005 and August 2011.

Participants {#s2b}
------------

Cases of proarrhythmia were included if they had one or more of the following criteria, all diagnosed as secondary to therapeutic drug administration or overdose: documented TdP, VF or VT (polymorphic or monomorphic, not associated with QT prolongation); exacerbation of pre-existing non-sustained arrhythmias to sustained; severe prolongation of the QTc interval corrected using Bazett's formula (\>500 ms) without symptoms; or moderate prolongation of the QTc interval (≥450 ms in men or ≥470 ms in women) with a clinical history of cardiac syncope.

All cases were reviewed by at least two experienced cardiologists, using hospital notes and interview questionnaire information, to ensure appropriate inclusion of cases. Patients with acute ischaemia, ischaemic polymorphic VT and structural heart disease (using symptoms, history of ischaemia and associated therapy, risk factors or ECG, stress test and coronary angiography results) were excluded. Case presentation (asymptomatic, syncope, VT, VF and/or TdP) and aetiology (QT prolongation-associated and non-QT prolongation-associated) were ascertained. Drugs received by the patient were adjudicated for culpability in contributing to proarrhythmia according to the clinical data, timing of medication and the presenting event that prompted referral. Prior reports of association with proarrhythmia were also taken into account, although drugs thought to contribute to causation but without such data were not excluded.

No sample size calculation could be performed for the study as, at the time of study initiation, the natural history, relative risk and potential risk factors of proarrhythmia were largely unknown.

Variables {#s2c}
---------

A proforma questionnaire obtained patients' self-reported information on age, gender, ethnicity, weight, height, smoking status, alcohol consumption, symptoms before, during and after the event (including 'blackout', 'near blackout', 'dizziness/light-headedness' and 'palpitations'), medication taken before, during and after the event (including prescription, over-the-counter/herbal and recreational), any medical and cardiovascular history (including angina, myocardial infarction, 'heart failure', 'heart valve problem', 'heart rhythm problem', 'high blood pressure', hypokalaemia, hypothyroidism, diabetes mellitus, 'stroke', transient ischaemic attack, 'liver problem', 'kidney problem') and family medical history (including 'sudden death' and 'unexplained blackout'). History of proarrhythmic events was validated using each patient's hospital notes and an ECG taken at the time of the interview. Patient hospital notes, where available, were also used to validate drug history (including the drug(s) considered to be related to the proarrhythmic event), and medical and cardiovascular history for all cases.

Culpable drugs were mapped to the Anatomical Therapeutic Chemical classification system. The drugs were then classified according to the CredibleMeds register risk of causing QT prolongation and/or TdP into the following groups: known risk, possible risk, conditional risk and no known risk. Drugs are classified as having known risk when there is substantial evidence for QT interval prolongation and TdP risk when used according to the label; possible risk when there is substantial evidence for QT interval prolongation but insufficient evidence of TdP risk when used according to the label; and conditional risk when there is substantial evidence for QT interval prolongation and TdP risk but only under specific conditions (eg, overdose, interaction with another drug). Drugs were also classified according to cytochrome (CYP) P450 activity (inhibitors and inducers), and potential pharmacodynamics interactions were identified using the Drug Interaction Checker (Medscape). Potential pharmacodynamics interactions were classified into one of the following groups: QTc prolongation; cardiotoxic (non-QTc prolongation-related but other cardiac effect likely, eg, bradycardia or other dysrhythmia); conditional (cardiac effect unclear but drug interaction has an impact on a proarrhythmic risk factor, eg, potassium levels); and other (non-cardiovascular) or no drug interaction.

Statistical methods {#s2d}
-------------------

Statistical analysis involved descriptive statistics, including measures of central tendency and dispersion for continuous variables (mean, SD, median, range and percentiles) and frequencies with proportions for categorical variables. Results were also stratified according to type of arrhythmia (QT prolongation-associated and/or non-QT prolongation-associated). All statistical analyses were performed using Stata V.12. Radar plots were also constructed in order to characterise cases and estimate the contribution of individual drugs to risk of proarrhythmia. Missing information relating to patients was described using a 'not known' category.

Results {#s3}
=======

Case characteristics {#s3a}
--------------------

The final overall cohort consisted of 130 cases ([figure 1](#F1){ref-type="fig"}), who were referred from a total of 98 consultant cardiologists across England ([figure 2](#F2){ref-type="fig"}). As the majority of cases were Caucasian (n=124, 95.4%), the analysis was performed on these individuals only. Characteristics of the final cohort of Caucasian cases are shown in [table 1](#T1){ref-type="table"}. Cases were 62.9% female with a median age at interview of 66 years (IQR 52--73 years). All cases were adults (≥18 years). Around a third (35.5%) had a family history of sudden death. The types of arrhythmia reported in cases are shown in [table 1](#T1){ref-type="table"}. The majority of cases reported TdP, VF or cardiac arrest with QT prolongation (n=79, 63.7%), of whom 56 (45.2%) presented with TdP, 13 (10.5%) presented with VF and 10 (8.1%) presented with TdP and VF. However, 23% (n=28) of cases involved VT or VF not related to QT prolongation. Median (SD) QTc values were 578 (69) ms in QT prolongation-associated cases and 466.7 (40) ms in non-QT prolongation-associated cases.

![Referrals and cohort accrual.](bmjopen-2017-016627f01){#F1}

![Geographical distribution of consultant cardiologists referring proarrhythmia cases.](bmjopen-2017-016627f02){#F2}

###### 

Characteristics of cases (n=124)

  Characteristics                                          n (% of cases)
  -------------------------------------------------------- ----------------
  Gender                                                   
   Female                                                  78 (62.9)
   Male                                                    46 (37.10)
  Age at interview (years)                                 
   10--19                                                  2 (1.6)
   20--29                                                  2 (1.6)
   30--39                                                  7 (5.7)
   40--49                                                  15 (12.1)
   50--59                                                  20 (16.1)
   60--69                                                  33 (26.6)
   70--79                                                  37 (29.8)
   80--89                                                  8 (6.5)
   Median (IQR)                                            66 (52--73)
  Smoking status                                           
   Current                                                 13 (10.5)
   Ex-smoker                                               58 (46.8)
   Never smoked                                            51 (41.1)
   Not known                                               2 (1.6)
  Alcohol use                                              
   Yes                                                     92 (74.2)
   No                                                      32 (25.8)
  Body mass index (kg/m^2^)                                
   \<18.5 (underweight)                                    5 (4.0)
   18.5--24.9 (normal)                                     55 (44.4)
   25--29.9 (overweight)                                   31 (25.0)
   ≥30 (obese)                                             33 (26.6)
  Family history                                           
   Unexplained syncope                                     17 (13.7)
   Sudden death                                            44 (35.5)
  Medical history\*                                        
   High blood pressure                                     66 (53.2)
   Hypokalaemia                                            33 (26.6)
   Hypothyroidism                                          22 (17.7)
   Angina                                                  26 (21.0)
   Myocardial infarction                                   27 (21.8)
   Heart failure                                           17 (13.7)
   Cardiomegaly                                            21 (16.9)
   Heart value problem                                     34 (27.4)
   Heart rhythm problem                                    90 (72.6)
   Stroke                                                  10 (8.1)
   Transient ischaemic attack                              11 (8.9)
   Diabetes mellitus                                       23 (17.7)
   Kidney disease                                          21 (16.9)
   Liver disease                                           10 (8.1)
  Type of arrhythmia/ECG abnormality                       
  QTp associated                                           **95 (76.6)**
   TdP, VF, cardiac arrest                                 79 (63.7)
   QTp \>500 ms without symptoms                           9 (7.3)
   QTp (≥450 ms in men or ≥470 ms in women) with syncope   7 (5.7)
  Not associated with QTp                                  **29 (23.4)**
   VT/VF                                                   28 (22.6)
   Exacerbation of pre-existing VT only                    1 (0.8)

\*Self-reported with validation from patient's hospital notes (where available).

QTp, QT interval prolongation; TdP, Torsade de Pointes; VF, ventricular fibrillation; VT, ventricular tachycardia.

Culpable drugs {#s3b}
--------------

A total of 165 patient drug exposures to 42 drugs deemed culpable were identified ([table 2](#T2){ref-type="table"}, two drugs were unspecified). The most frequently associated drug class was the antiarrhythmics, with 70 drug exposures (42.4% of drug exposures) in 67 (54.0%) patients. Amiodarone (n=40; 24.2% of drug exposures; 32.3% of patients), flecainide (n=23; 13.9% of drug exposures; 18.6% of patients) and sotalol, a beta-blocker with class III properties (n=25; 15.2% of drug exposures; 20.2% of patients), were the most frequently reported single drug causes and known to carry a risk of QTc prolongation and/or TdP. Antibiotics (eg, erythromycin; n=5, 3.0% of drug exposures; 4.0% of patients) and antidepressants (eg, citalopram; n=7, 4.2% of drug exposures; 5.7% of patients) were also implicated.

###### 

Drugs culpable in proarrhythmia cases, stratified by risk of QT prolongation and/or Torsades de Pointes

  Drug name                 ATC code   Drug type                              Drug exposures (n)   \%
  ------------------------- ---------- -------------------------------------- -------------------- -----------
  Known risk                                                                                       
   Amiodarone               C01BD01    Antiarrhythmic                         40                   24.2
   Sotalol                  C07AA07    Beta-blocking agent/antiarrhythmic     25                   15.2
   Flecainide               C01BC04    Antiarrhythmic                         23                   13.9
   Citalopram               N06AB04    Antidepressant                         7                    4.2
   Erythromycin             J01FA01    Antibacterial                          5                    3.0
   Clarithromycin           J01FA09    Antibacterial                          4                    2.4
   Disopyramide             C01BA03    Antiarrhythmic                         4                    2.4
   Domperidone              A03FA03    Propulsive                             4                    2.4
   Fluconazole              J02AC01    Antimycotic                            2                    1.2
   Thioridazine             N05AC02    Antipsychotic                          2                    1.2
   Ciprofloxacin            J01MA02    Antibacterial                          1                    0.6
   Haloperidol              N05AD01    Antipsychotic                          1                    0.6
   Methadone                N07BC02    Drug used in addictive disorders       1                    0.6
   Pimozide                 N05AG02    Antipsychotic                          1                    0.6
  Possible risk                                                                                    
   Venlafaxine              N06A×16    Antidepressant                         3                    1.8
   Antihistamine            R06A       Antihistamine                          1                    0.6
   Capecitabine             L01BC06    Antimetabolite                         1                    0.6
   Clomipramine             N06AA04    Antidepressant                         1                    0.6
   Olanzapine               N05AH03    Antipsychotic                          1                    0.6
   Tamoxifen                L02BA01    Antioestrogen                          1                    0.6
  Conditional risk                                                                                 
   Furosemide               C03CA01    Diuretic                               5                    3.0
   Amitriptyline            N06AA09    Antidepressant                         3                    1.8
   Bendroflumethiazide      C03AA01    Diuretic                               2                    1.2
   Fluoxetine               N06AB03    Antidepressant                         2                    1.2
   Amisulpride              N05AL05    Antipsychotic                          1                    0.6
   Paroxetine               N06AB05    Antidepressant                         1                    0.6
   Quinine                  P01BC01    Antimalarial                           1                    0.6
   Trazodone                N06A×05    Antidepressant                         1                    0.6
  Drugs to avoid in cLQTS                                                                          
   Trimethoprim             J01EA01    Antibacterial                          1                    0.6
  No known risk                                                                                    
   Digoxin\*                C01AA05    Cardiac glycoside                      4                    2.4
   Propafenone              C01BC03    Antiarrhythmic                         3                    1.8
   Cetirizine†              R06AE07    Antihistamine                          1                    0.6
   Chlorpheniramine         R06AB02    Antihistamine                          1                    0.6
   Dosulepin                N06AA16    Antidepressant                         1                    0.6
   Lofexidine‡              N07BC04    Drug used in addictive disorders       1                    0.6
   Loratadine               R06A×13    Antihistamine                          1                    0.6
   Procaine                 S01HA05    Local anaesthetic                      1                    0.6
   Theophylline             R03DA04    Drug for obstructive airways disease   1                    0.6
   Thiazide                 C03        Diuretic                               1                    0.6
   Timoptol\*               C07AA06    Beta-blocking agent                    1                    0.6
   Statin                   C10A       Lipid-modifying agent                  1                    0.6
   Verapamil†               C08DA01    Calcium-channel blocker                1                    0.6
  Unspecified               --         --                                     2                    1.2
  Total                     --         --                                     **165**              **100.0**

\*Contributed to bradycardia.

†Not classified---these drugs have been reviewed by CredibleMeds; however, classification could not be performed based on the evidence available and there is no indication the drugs are free of risk of QTp/TdP.

‡Under active review for possible risk of QTp/TdP.

ATC, Anatomical Therapeutic Chemical; cLQTS, congenital long QT syndrome; QTp, QT interval prolongation; TdP, Torsades de Pointes.

Of the 42 culpable drugs, 14 (33.3%) drugs carried a known risk (120 (72.7%) drug exposures), 8 (19.0%) carried a conditional risk (16 (9.7%) drug exposures), 6 (14.3%) carried a possible risk (7 (4.2%) drug exposures), 1 (2.4%) carried a risk in individuals with cLQTS, and 13 (31.0%) carried no known risk of QTc prolongation and/or TdP (18 (10.9%) drug exposures). The level of risk could not be established for two drugs.

Of the 13 culpable drugs carrying no known risk of QTc prolongation and/or TdP, 2 are known to contribute to bradycardia (timolol and digoxin), 2 are 'not classified' according to CredibleMeds based on the evidence available (cetirizine and verapamil) and 1 remains under active review (lofexidine).

Multiple drug combinations ([table 3](#T3){ref-type="table"}) were reported in 32 (25.8%) patients. Specifically, 27 (21.8%) patients reported two drugs, 2 (1.6%) patients reported three drugs, 2 (1.6%) patients reported four drugs and 1 (0.8%) patient reported five drugs. Two patients had unspecified drug combinations. Of the patients reporting more than one drug, 84.4% (27/32) reported using at least one cytochrome P450 inhibitor, with 6 (18.8%) using two or more in combination. A single patient reported using a CYP inducer. Potential pharmacodynamics interactions within patients reporting more than one drug, according to the Medscape Drug Interaction Checker, were QTc prolongation (19/32, 59.4%), cardiotoxic (3/32, 9.4%), conditional (1/32, 3.1%) and other (non-cardiovascular; 2/32, 3.6%) interactions. Seven patients (21.9%) reported a drug combination without a potential drug interaction.

###### 

Drug combinations culpable in cases of proarrhythmia

  Drug 1                 Drug 2           Drug 3          Drug 4          Drug 5    Patients with combination (n)   Potential DDI   Drugs (n)               
  ---------------------- ---------------- --------------- --------------- --------- ------------------------------- --------------- ----------- --- --- --- ---
   Amiodarone            Furosemide                                                 3                               None            1           0   1   1   0
   Citalopram            Flecainide                                                 2                               QTp             2           0   0   1   0
   Amiodarone            Amitriptyline                                              1                               QTp             1           0   1   1   0
   Amiodarone            Digoxin                                                    1                               Cardiotoxic     1           0   0   1   0
   Amiodarone            Sotalol                                                    1                               QTp             2           0   0   1   0
   Amiodarone            Domperidone                                                1                               QTp             2           0   0   1   0
   Amiodarone            Flecainide                                                 1                               QTp             2           0   0   1   0
   Amiodarone            Disopyramide                                               1                               QTp             2           0   0   1   0
   Amiodarone            Statin                                                     1                               Other           1           0   0   1   0
   Amiodarone            Trimethoprim                                               1                               QTp             1           0   0   2   0
   Amiodarone            Erythromycin                                               1                               QTp             2           0   0   2   0
   Bendroflumethiazide   Venlafaxine                                                1                               None            0           1   1   0   0
   Bendroflumethiazide   Cetirizine                                                 1                               None            0           0   1   0   0
   Chlorpheniramine      Olanzapine                                                 1                               Other           0           1   0   1   0
   Ciprofloxacin         Tamoxifen                                                  1                               None            1           1   0   1   0
   Clarithromycin        Fluconazole                                                1                               QTp             2           0   0   2   0
   Clomipramine          Dosulepin                                                  1                               QTp             0           1   0   1   0
   Digoxin               Timoptol                                                   1                               Cardiotoxic     0           0   0   0   0
   Disopyramide          Flecainide                                                 1                               QTp             2           0   0   0   0
   Flecainide            Furosemide                                                 1                               None            1           0   1   0   0
   Paroxetine            Thiazide                                                   1                               Conditional     0           0   1   1   1
   Sotalol               Fluoxetine                                                 1                               QTp             1           0   1   1   0
   Methadone             Venlafaxine                                                1                               QTp             1           1   0   1   0
   Thioridazine          Fluoxetine                                                 1                               QTp             1           0   1   0   0
   Amiodarone            Domperidone      Fluconazole                               1                               QTp             3           0   0   2   0
   Amiodarone            Furosemide       Digoxin                                   1                               Cardiotoxic     1           0   1   1   0
   Amiodarone            Clarithromycin   Antihistamine   Digoxin                   1                               QTp             2           1   0   2   0
   Haloperidol           Clarithromycin   Citalopram      Amitriptyline             1                               QTp             3           0   1   3   0
   Citalopram            Domperidone      Amitriptyline   Procaine        Quinine   1                               QTp             2           0   2   1   0

DDI, drug drug interaction; QTp, QTc interval prolongation.

Types of arrhythmia {#s3c}
-------------------

Types of proarrhythmia identified within this study included QT prolongation-related (n=95, 76.6%) and non-QT prolongation-related (n=29, 23.4%), the latter more typically associated with QRS prolongation ([table 2](#T2){ref-type="table"}). Stratification according to proarrhythmia type demonstrated few differences between the characteristics of QT prolongation-related and non-QT prolongation-related cases of proarrhythmia, with similar frequency of past medical conditions within both types ([figure 3](#F3){ref-type="fig"}). Similarly drugs deemed culpable in cases of proarrhythmia were similar between these types, except for flecainide, which was more commonly implicated with non-QT prolongation-related compared with QT prolongation-related ([figure 4](#F4){ref-type="fig"}).

![Characteristics of QTp-related and non-QTp-related cases of proarrhythmia. FH, family history; QTp, QT interval prolongation; TIA, transient ischaemic attack.](bmjopen-2017-016627f03){#F3}

![Drugs (Anatomical Therapeutic Chemical codes) culpable in cases of proarrhythmia. QTp, QT interval prolongation.](bmjopen-2017-016627f04){#F4}

Discussion {#s4}
==========

The DARE study established a cohort of 130 cases of clinically validated drug-induced proarrhythmia referred from across England. To our knowledge this is the largest single study describing a cohort of cases of drug-induced arrhythmia. This information can be used in conjunction with other methods for evaluating the risk of drug-induced arrhythmias, such as spontaneous reports, healthcare databases and active surveillance studies. An analysis of 124 Caucasian cases was undertaken. These Caucasian cases were predominantly female (62.9%) and middle-aged or elderly (median age at interview of 66 years (IQR 52--73 years)). The majority reported significant past cardiac comorbidity including heart rhythm problems (72.6%), high blood pressure (53.2%), heart valve problems (27.4%), angina (21.0%) and myocardial infarction (21.8%). This is consistent with data that demonstrate arrhythmia or heart failure to be a risk for proarrhythmia.[@R31] Over a third of cases also had an associated family history of sudden death, supporting the potential genetic risk for drug-induced arrhythmia.[@R21] Additionally, over a quarter of cases presented with hypokalaemia (26.6%). Hypokalaemia is associated with QT interval prolongation due to increased competitive blockade of I~Kr~, which causes loss of function of the hERG (human Ether-a-go-go Related Gene) channel.[@R16]

Risk factors for proarrhythmia have been studied before. For example, one study demonstrated hypokalaemia, myocardial infarction, sepsis and heart failure to be risk factors for QT prolongation in both drug-induced and non-drug-induced hospitalised cases.[@R32] Furthermore, a study of 21 patients with drug-induced QT prolongation from a Greek hospital found hypertension, female gender, paroxysmal atrial tachyarrhythmias and old age (\>60 years) to be common characteristics of patients presenting with the condition.[@R33] A study of a group of methadone users in Switzerland demonstrated greater risk of QT prolongation with hypokalaemia, higher methadone dose, altered liver function and use of P450 cytochrome inhibitors.[@R34] Finally, a study of psychiatric patients with drug-induced LQTS showed hypokalaemia, abnormal T wave as well as hepatitis C and HIV infection to increase the risk of LQTS in this population.[@R35]

In our study amiodarone, sotalol and flecainide were the most common culpable drugs as was the antiarrhythmic drug group as a whole (42.2% of drug exposures). Their high prevalence may be due to the relative high potency of cardiac current blockade and/or reflect that cardiologists were the main referral source of cases. For example clinical trials of patients with ventricular and supraventricular arrhythmias treated with sotalol have shown a 4.3% prevalence of proarrhythmia.[@R36] While class Ia, Ic and III antiarrhythmics carry a known risk of QT prolongation and/or TdP and can be potent IKr blockers, amiodarone is often thought of as a rare cause of TdP.[@R37] Its importance in our cohort may be due to its relatively frequent use as an antiarrhythmic agent and/or that those most vulnerable to aLQTS (ie, elderly women with cardiac comorbidity) are more likely to receive amiodarone than other antiarrhythmics due to its perceived lower proarrhythmic risk. This is therefore an important warning to clinicians. Proarrhythmia unrelated to QT prolongation was most commonly observed in users of flecainide, recognised to result from conduction slowing, causing QRS duration prolongation.[@R38] Amiodarone was also frequently reported to be associated with LQTS and TdP in a recent active surveillance study of 58 cases in Germany, a study that showed similar results to DARE, including the identification of hypokalaemia as a risk factor for LQTS and TdP.[@R39]

Nearly three-quarters of the culpable drug exposures were caused by drugs with known risk of QT prolongation and/or TdP, including antibiotics and antidepressants. However, 13 (31.0%) different drugs were diagnosed as culpable in proarrhythmia but not recognised as having such a risk according to the CredibleMeds register. Two are known to contribute to bradycardia (a risk for proarrhythmia), two are 'not classified' according to CredibleMeds based on the evidence available and one remains under active review (lofexidine). Drug combinations were also culpable in a quarter of cases, with up to five drugs being reported in combination. Of these drug combinations by far the majority, 84.4% (27/32), included at least one cytochrome P450 inhibitor. Drug combinations of antipsychotics and antidepressants have also previously been shown to increase the risk of QT interval prolongation when compared with antipsychotics alone.[@R40] Concurrent use of more than one QT-prolonging drug or concurrent use with a drug that alters the pharmacokinetic profile of the drug is an important risk factor for adverse outcomes. On the other hand, other studies have shown no increased risk of QT interval prolongation with the use of multiple QT-prolonging drug combinations compared with single drugs.[@R32] Furthermore, drugs with no known risk of QTc prolongation when used alone may result in prolongation of the QTc interval when used in combination. For example, ceftriaxone and lansoprazole were identified as having a risk of QTc prolongation when used together using electronic healthcare records and in vitro methodology.[@R41] Drug interactions were also reported to represent a high proportion of cases of drug-induced TdP within a Belgium study using the EudraVigilance database (18 of 31 cases).[@R42]

Limitations of the DARE study include the inability to enrol patients who may have suffered from sudden death as a result of drug-induced arrhythmia; for ethical reasons only live patients could be included. Furthermore, as all referrals came from cardiologists, this may have resulted in selection bias and underestimation of the prevalence of drug-induced arrhythmia from non-cardiac drugs. The level of underestimation due to sudden death or cardiologist referral is difficult to quantify. Determining the cause of death in patients with sudden cardiac death is challenging, with ion channelopathies potentially accounting for 40% of cases of sudden arrhythmic death syndrome, being undetectable after a patient has died.[@R43] A comparison with spontaneous reports of drug-induced arrhythmia might provide information on the level of underestimation of the prevalence of drug-induced arrhythmia from non-cardiac drugs; however, under-reporting of severe adverse drug reactions is known to be high, at approximately 80%.[@R44] In addition, patient answers to questionnaires may have been subject to recall bias and some of the patient information could not be validated from patient records. Finally, differences in ethnicity could not be investigated in this group as there were too few cases of non-Caucasian ethnic origin. Ethnic differences have been shown to affect the risk of QT prolongation due to polymorphisms in cardiac ion channels.[@R45] With a larger number of cases, ethnicity differences could be further investigated. It would also be desirable to estimate the incidence of proarrhythmia within the UK population, as has been done for a similar study.[@R39] Future work might also involve an investigation of specific drug types and how exposure duration and patterns of usage might affect the risk of proarrhythmias.

Conclusions {#s5}
===========

Increased awareness in the past decade of the public health risk of QT-prolonging drugs has resulted in the regulatory authorities producing guidelines for studying the potential for QT prolongation in premarketing development and the adoption of risk-minimisation measures.[@R29] However, due to rarity and diagnostic difficulties, the lack of reported TdP cases in premarketing or postmarketing safety monitoring is a challenge for drug safety.[@R46] To date, linked epidemiological and pharmacogenetic data on proarrhythmic events have been lacking. As such, the DARE study has allowed the development of a cohort of cases that provide crucial safety information, as well as underlying clinical and genetic data.[@R18] DARE has provided information that confirms risk factors for proarrhythmia, including patient comorbidities and use of drugs with known QTc prolongation risk. However, the study has also identified higher frequency of amiodarone as well as reports of drugs with no known QTc prolongation risk.

Caution is necessary when prescribing class I and III antiarrhythmic drugs. These include amiodarone given its frequent use in clinical practice. The prescriber needs to be aware of a patient's concomitant medications and comorbidities, especially middle-aged to elderly women with cardiovascular disease and/or a family history of sudden death, as well as the likelihood of hypokalaemia. Furthermore prescribers must be aware of the contribution of non-cardiac drugs to the burden of drug-induced arrhythmias,[@R49] with approximately 3% of prescriptions in the UK representing non-cardiac drugs with warnings for arrhythmic potential.[@R50] Our findings reinforce the need for safer prescribing of proarrhythmic drugs in clinical practice.
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